Suzhou Zelgen Completes Phase II Study of Jakinib for Ankylosing Spondylitis
Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266) announced the successful completion of a multi-center, randomized...
Hubei Province Proposes National TCM Patent Medicine Procurement Alliance
The Healthcare Security Administration of Hubei Province has proposed the establishment of a national traditional...
Buchang Pharmaceuticals Gains NMPA Approval for BC008-1A Clinical Study
China-based Shandong Buchang Pharmaceuticals Co., Ltd (SHA: 603858) announced that it has received approval from...
CDE Prioritizes Review of Pearl Bio’s Breatinib for NSCLC Treatment
The Center for Drug Evaluation (CDE) website indicates that Beijing Pearl Biotechnology Co., Ltd’s APL-101/PLB1001...
Jiangsu Hengrui Medicine Gains NMPA Approval for HRS-6209 Clinical Study
China-based Jiangsu Hengrui Medicine Co., Ltd (SHA: 600276) announced that it has received approval from...
I-Mab’s Lemzoparlimab Gains CDE Approval for HR-MDS Phase III Trial
China-based I-Mab (NASDAQ: IMAB) announced that it has successfully completed an End-of-Phase 2 (EoP2) meeting...
Takeda’s Modakafusp Alfa and TAK-981 Gain NMPA Clinical Trial Approvals
The National Medical Products Administration (NMPA) website indicates that Japan-based Takeda Pharmaceutical Co., Ltd’s (TYO:...
Huahai Pharmaceutical Gains FDA Approval for Generic Fingolimod
China-based Zhejiang Huahai Pharmaceutical Co., Ltd (SHA: 600521) announced that it has received Abbreviated New...
Vathin Medical Instrument Raises Pre-Series B Funding Led by IDG Capital
China-based single-use bronchoscope specialist Hunan Vathin Medical Instrument Co., Ltd reportedly raised “hundreds of millions”...
NMPA Issues Guidelines on Medical Device Grading Administration
The National Medical Products Administration (NMPA) has released a set of Guiding Opinions on “Medical...
Frontier Biotech’s FB2001 Inhalant Accepted for NMPA Review
China-based Frontier Biotechnologies Inc. (SHA: 688221) announced that a registrational clinical filing for its FB2001...
Luye Pharma’s LY03015 Receives FDA Approval for Phase I Clinical Study
China-based Luye Pharma Group (HKG: 2186) announced that it has received approval from the US...
Hengrui Medicine to Incentivize Employees with Share Distribution
China-based Jiangsu Hengrui Medicine Co., Ltd (SHA: 600276) has announced plans to incentivize its employees...
Biden’s Executive Order Boosts US Bio-Economy, Targets China’s Biotech Rise
US President Joe Biden signed an executive order on Monday, outlining steps to bolster the...
QuantuMDx and Sansure Biotech Partner to Commercialize Q-POC in China
UK-based QuantuMDx Group Ltd announced a global R&D, manufacturing, and commercial partnership with China’s Sansure...
InnoCare Pharma’s BCL2 Inhibitor ICP-248 Gains NMPA Approval for Clinical Study
China’s Beijing InnoCare Pharma (HKG: 9969) announced that it has received approval from the National...
BeiGene’s Tislelizumab Meets Primary Endpoint in HCC Study at ESMO
BeiGene (NASDAQ: BGNE, HKG: 6160, SHA: 688235) presented the latest results of the global Phase...
Luye Pharma’s BA-CovMab Receives NMPA Approval for COVID-19 Clinical Trials
China-based Luye Pharma Group (HKG: 2186) announced that its subsidiary Shandong BoAn Biotechnology Co., Ltd’s...
Jiangsu Healthcare to Cover All Psychological Treatments Under BMI
The Jiangsu Provincial Healthcare Security Administration is reportedly considering adding all psychological diagnosis and treatment...
Leadinno Medical Valley Raises RMB 100M in Series A Financing for Neuromodulation Devices
Beijing-based neuromodulation medical device maker Leadinno Medical Valley reportedly raised over RMB 100 million (USD...